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Purpose: Precocious puberty has significantly increased recently. While obesity 
is associated with puberty timing, the relationship between obesity and central 
precocious puberty (CPP) remains controversial. The purpose of this study was to 
determine whether insulin resistance is associated with bone age (BA) advancement 
in girls with CPP.
Methods: We retrospectively analyzed the records of 804 girls referred for puberty 
evaluation. Anthropometric measurements, BA, sex hormone, sex hormone binding 
globulin (SHBG), and insulin levels, lipid profiles, and gonadotropin releasing 
hormone stimulation tests were assessed. Insulin resistance parameters were 
calculated using the homeostasis model assessment-insulin resistance (HOMA-IR) 
and quantitative insulin sensitivity check index (QUICKI) models.
Results: BA, BA advancement, free estradiol index, insulin, and HOMA-IR increased 
significantly in girls with high body mass index (BMI) compared with that of 
girls with low BMI in cases of CPP. HOMA-IR was positively correlated with BA 
advancement and BMI but negatively correlated with SHBG. QUICKI was negatively 
correlated with BA advancement and BMI and positively correlated with SHBG. 
When HOMA-IR increased by 1, the odds for BA advancement increased 120% after 
adjusting for age and BMI (P=0.033). 
Conclusion: Insulin resistance could be associated with BA advancement in girls 
with CPP. 
Keywords: Precocious puberty, Luteinizing hormone, Gonadotropin-releasing 
hormone
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Introduction
Recently, a shift in pubertal timing has been reported worldwide1). Historical data from 
several countries shows that the average menarcheal age has decreased remarkably2). A recent 
study suggests similar decreases in average menarcheal age in Korean girls3). Consequently, the 
prevalence of precocious puberty has increased in Korea and it is becoming a social concern4).
Various factors appear to affect the timing of pubertal development, including the 
environment and nutrition. Adequate nutrition is important for normal timing of pubertal 
development, and poor childhood nutrition delays growth and pubertal onset5). The increase 
of precocious puberty in girls has been coincided by increases in childhood obesity6). Insulin 
resistance is associated with obesity and is a key risk factor for type 2 diabetes mellitus, cardio­
vascular disease, and dyslipidemia in adulthood7). Early pubertal timing in girls may be asso­
ciated with early insulin resistance and cardiometabolic diseases in adults8).
However, the relationship between obesity for precocious puberty remains a controversial 
topic. Bordini et al.9) suggested that excess weight, in the absence of excess sex steroid, may 
subtly suppress hypothalamic­pituitary­gonadal function in premenarcheal pubertal girls. 
Jasik and Lustig10) reported that there is little support for an association between weight gain 
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and early menarche.
Some groups have studied the relation of central precocious 
puberty (CPP) and obesity, particularly insulin resistance, but 
clinical studies are still lacking11,12). The purpose of this study 
was to evaluate the influence of obesity in girls with CPP. We 
analyzed differences in pubertal characteristics according to 
body mass index (BMI) and the correlation between insulin 
resistance and biochemical characteristics in girls with CPP. 
Furthermore, we investigated the association between pubertal 
characteristics including bone age (BA) advancement and 
insulin resistance. 
Materials and methods
1. Study population and design
We retrospectively reviewed the medical records of 804 
girls referred for evaluation of puberty from 2011 to 2015. 
We included girls younger than 8 years with objective breast 
budding above Tanner stage II13). We reviewed gonadotropin 
releasing hormone (GnRH) stimulation test results and defined 
CPP as peak luteinizing hormone (LH)≥5 IU/L and non­CPP 
as peak LH<5 IU/L. We excluded patients with tests collected 
under nonfasting condition, incomplete sex hormone studies, 
and history of any other systemic diseases. Therefore, 164 girls 
were included in the CPP group, and 99 girls were included in 
the non­CPP group. The control group comprised age­ and sex­
matched healthy girls (n=67) who did not have objective breast 
budding, that is, Tanner stage I. The study design is shown in Fig. 
1. This study was approved by the Institutional Review Board 
of Yonsei University Severance Hospital (approval number: 
3­2015­0336). Written informed consent was obtained from all 
patients.
2. Clinical and laboratory data
BA was evaluated by a single pediatric radiologist measured 
by 6 months scale with Greulich and Pyle method. BMI was 
calculated as weight divided by height squared. The data for 
height standard deviation scores (SDS), weight SDS, and BMI 
SDS were calculated using z­scores from the 2005 Korean 
National Growth Chart14).
The hypothalamic­pituitary­gonadal axis was determined 
using GnRH stimulation test results. Basal serum samples were 
obtained before GnRH injection (100­μg Relefact; Sanofi­
Aventis, Paris, France). Serum LH and follicle­stimulating 
hormone levels were measured using a chemiluminescence im­
munoassay with an analytical sensitivity of 0.2 IU/L (Beckman 
Coulter, Brea, CA, USA). Estradiol (E2) levels were determined 
using an electrochemiluminescence immunoassay with an 
analytical sensitivity of 5 pg/mL (Roche, Basel, Switzerland). 
Sex hormone binding globulin (SHBG) was determined 
using an electrochemiluminescence immunoassay (Roche, 
Basel, Switzerland). Free estradiol index (FEI) was calculated 
by dividing the serum E2 level (pg/mL) by the serum SHBG 
level (nmol/L) and multiplying by 100. The molar ratio of E2/
SHBG was calculated to convert E2 to picomolar, the picogram 
per milliliter value is multiplied by 3.67. A peak LH of at least 
5 IU/L was used as the cutoff criteria for pubertal response for 
the GnRH stimulation test. Insulin­like growth factor­1 (IGF­
8 years 8 years
8 years
* † ǂ
Fig. 1. Summary of patients and study design in this study. CPP*, non-CPP†, and control‡. CPP, 
central precocious puberty; GnRH, gonadotropin releasing hormone; LH, luteinizing hormone.
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1) was measured using a solid­phase, enzyme­labeled, 2­site 
chemiluminescent immunometric assay (Siemens, Munich, 
Germany). We reviewed medical records to obtain total 
cholesterol, low­density lipoprotein cholesterol, high­density 
lipoprotein cholesterol, triglyceride, fasting serum glucose, 
alanine aminotransferase, and insulin levels. These tests were 
performed in a fasting state over 8 hours. Insulin resistance was 
assessed from fasting plasma glucose (G0, in mg/dL) and fasting 
plasma insulin (I0, mU/L) levels using the homeostasis model 
assessment­insulin resistance (HOMA­IR) and quantitative 
insulin sensitivity check index (QUICKI) models. HOMA­IR 
was calculated as I0 × G0 / 405
15), and QUICKI was calculated as 
1/(logG0 + logI0)
16).
3. Statistical analysis
We analyzed data with SAS ver. 9.4 (SAS Institute Inc., Cary, 
NC, USA). We used independent­samples T­test and analysis 
of variance (ANOVA) to compare the clinical and biochemical 
characteristics between the CPP, the non­CPP, and the control 
groups. We used ANOVA to compare the characteristics in the 
groups categorized according to BMI scores. We used a trend 
test to determine the significance of the increase or decrease in 
the variables as the increasing BMI. Pearson correlation analysis 
was used to define the correlation between each characteristic 
and insulin resistance. Multiple logistic regression analysis was 
used to determine the correlation between insulin resistance 
parameters and BA advancement. We suggested 2 models 
adjusted for associated variables such as age and BMI. P­values 
less than 0.05 were considered statistically significant. Multiple 
comparisons were adjusted by Bonferroni correction.
Results
1. The comparison of the baseline clinical, biochemical
    characteristics and insulin resistance parameters of 
    CPP, non-CPP, and control groups
We compared the baseline characteristics of the CPP, non­
CPP, and control groups (Table 1). BA and baseline serum LH, 
Table 1. The comparison of the baseline clinical, biochemical characteristics and insulin resistance parameters of CPP, non-CPP, and 
control groups (n=330)
Characteristic CPP (n=164) Non-CPP (n=99) Control (n=67) P-value* P-value† P-value‡ Overall P-value§
CA (yr) 8.3±0.6 8.1±0.8 7.9±0.6 0.001 0.077 0.056 0.001
BA (yr) 9.7±0.9 9.2±1.0 8.2±0.9 0.001 0.001 0.003 0.001
BA–CA (yr) 1.3±0.7 1.1±0.7 0.0±1.5 0.001 0.001 0.117 0.001
Ht. SDS 0.9±1.1 0.8±1.0 0.5±0.9 0.011 0.063 0.999 0.012
Wt. SDS 0.7±1.3 0.9±1.3 0.5±0.9 0.714 0.142 0.782 0.138
BMI SDS 0.3±1.1 0.9±1.3 0.4±0.9 0.999 0.633 0.237 0.195
SHBG (nmol/L) 80.2±36.7 76.5±34.7 83.3±31.5 0.999 0.671 0.999 0.460
LH0 (IU/L) 1.1±1.2 0.5±0.4 0.3±0.3 0.001 0.615 0.001 0.001
Peak LH (IU/L) 12.9±9.5 3.2±1.0 - - - 0.003 0.001
Peak LH/LH0 23.3±22.7 9.3±5.8 - - - 0.003 0.001
E2 (pg/mL) 12.0±12.5 9.5±9.0 5.0±0.3 0.001 0.016 0.162 0.001
FEI (pmol/L) 17.8±18.3 15.3±17.1 7.0±2.7 0.001 0.004 0.675 0.001
IGF-1 (ug/L) 271.6±91.4 238.9±70.9 220.6±64.3 0.001 0.463 0.005 0.001
AST (IU/L) 27.3±8.9 28.6±10.3 27.1±5.1 0.999 0.883 0.713 0.433
ALT (IU/L) 14.8±5.7 17.5±12.1 14.8±6.7 0.999 0.112 0.037 0.028
Total cholesterol (mg/dL) 168.5±28.7 164.7±27.2 169.4±23.0 0.999 0.831 0.842 0.457
Triglycerides (mg/dL) 116.0±68.6 109.5±61.6 111.4±58.1 0.999 0.999 0.999 0.718
LDL-cholesterol (mg/dL) 94.6±27.1 93.5±26.6 95.9±21.8 0.999 0.999 0.999 0.850
HDL-cholesterol (mg/dL) 51.2±10.1 50.4±9.9 51.8±8.5 0.999 0.999 0.999 0.637
Fasting plasma glucose (mg/dL) 94.7±11.1 96.1±11.9 91.8±8.1 0.204 0.035 0.864 0.040
Insulin (μU/mL) 23.5±22.9 22.5±26.5 12.0±6.8 0.001 0.008 0.999 0.001
HOMA-IR 5.69±5.85 5.68±7.37 2.78±1.72 0.002 0.005 0.999 0.002
QUICKI 0.32±0.04 0.33±0.05 0.34±0.04 0.003 0.194 0.390 0.004
Values are presented as mean±standard deviation.
CPP, central precocious puberty; CA, chronological age; BA, bone age; SDS, standard deviation scores; Ht., height; Wt., weight; BMI, body 
mass index; SHBG, sex hormone binding globulin; LH, luteinizing hormone; E2, estradiol; FEI, free estradiol index; IGF-1, insulin-like growth 
factor-1; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDL, low-density lipoprotein; HDL, high-density lipoprotein; 
HOMA-IR, homeostasis model assessment-insulin resistance; QUICKI, quantitative insulin sensitivity check index   
*P-value for CPP vs. control group. †P-value for non-CPP vs. control group. ‡P-value for CPP vs. non-CPP group §P-value was calculated by 
analysis of variance.
Multiple comparison was adjusted by Bonferroni correction.
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E2, FEI, IGF­1, and insulin levels were higher in the CPP group 
than in the control group. The HOMA­IR was higher in the CPP 
group than in the control group (P=0.002). The QUICKI was 
lower in the CPP group than in the control group; therefore, this 
parameter indicated high insulin resistance in the CPP group 
(P=0.003). 
2. Baseline clinical, biochemical characteristics and insulin
    resistance parameters according to BMI in CPP group
We categorized the girls with CPP into 3 groups according 
to BMI (BMI<50th percentile, 50th percentile≤BMI<85th 
percentile, and BMI≥85th percentile) and compared clinical and 
biochemical characteristics. BA, BA advancement, FEI, alanine 
aminotransferase, insulin, and HOMA­IR were significantly 
higher in girls with high BMI than in girls with low BMI. Each 
of the variables showed an increasing trend with higher BMI. 
SHBG and QUICKI were lower in girls with high BMI than in 
girls with low BMI. Each of the variables showed a decreasing 
trend with higher BMI (Table 2).
3. The correlation between clinical, biochemical 
    characteristics and insulin resistance parameters in 
    total girls
We analyzed all girls including CPP, non­CPP, and control 
groups. Pearson correlation analysis results for HOMA­IR and 
QUICKI for all of girls showed that HOMA­IR was positively 
correlated with BA advancement, BMI SDS, FEI, IGF­1, and 
triglycerides and was negatively correlated with SHBG. QUICKI 
was negatively correlated with BA advancement, BMI­SDS, 
baseline LH, and FEI and was positively correlated with SHBG 
(Table 3).
4. The change of BA advancement associated with 
    insulin resistance
We used logistic regression analysis to determine the probabi­
lity of precocious puberty according to changes in the insulin 
resistance parameters. We also analyzed all girls to clarify the 
relationship between insulin resistance and BA advancement. 
When HOMA­IR increased by 1, the odds for BA advancement 
increased 119% (P=0.033). We analyzed the odds after adjusting 
for chronological age (model 1) and both chronological age 
and BMI (model 2) to exclude the influence of them. Similar 
results were achieved through models 1 and 2. When QUICKI 
increases by 0.01, the odds for BA advancement increased 92% 
(P=0.030). After adjusting for age and both age and BMI, the 
odds were similar but not significant (Table 4).
Discussion
Trends toward early pubertal timing have coincided with 
increased obesity prevalence17). Known factors that affect timing 
Table 2. Baseline clinical, biochemical characteristics and insulin resistance parameters according to BMI in CPP group (n=164)
Characteristic BMI<50th %ile (n=87) 50th %ile≤BMI<85th %ile (n=57) BMI≥85th %ile (n=20) P-value* P for trend†
CA (yr) 8.3±0.6 8.4±0.6 8.2±0.7 0.482 0.960
BA (yr) 9.6±0.9 9.6±0.9 10.2±1.0 0.018 0.018
BA–CA (yr) 1.2±0.7 1.2±0.7 2.0±0.9 0.001 0.001
SHBG (nmol/L) 98.6±34.2 66.0±27.2 40.7±17.0 0.001 0.001
LH0 (IU/L) 1.1±1.3 1.1±1.3 1.1±0.8 0.952 0.842
Peak LH (IU/L) 12.7±9.7 13.3±9.2 12.5±9.9 0.924 0.953
E2 (pg/mL) 13.2±14.1 10.3±10.3 11.2±9.6 0.367 0.259
FEI (pmol/L) 15.0±16.7 18.1±18.7 29.5±20.1 0.007 0.004
IGF-1 (ug/L) 278.4±94.0 251.5±87.4 298.9±83.5 0.081 0.950
AST (IU/L) 26.4±5.7 29.6±12.5 24.3±6.8 0.032 0.887
ALT (IU/L) 12.8±3.4 16.1±6.0 19.8±8.0 0.001 0.001
Total cholesterol (mg/dL) 165.6±25.7 174.0±33.2 165.2±26.2 0.198 0.457
Triglycerides (mg/dL) 108.3±72.8 122.4±66.3 130.9±53.4 0.284 0.117
LDL-cholesterol (mg/dL) 92.8±27.3 98.3±26.6 92.4±27.6 0.457 0.630
HDL-cholesterol (mg/dL) 52.0±10.5 51.2±9.6 46.9±8.7 0.139 0.081
Fasting plasma glucose (mg/dL) 94.3±11.6 94.4±11.2 96.9±8.1 0.647 0.461
Insulin (μU/mL) 17.2±13.9 23.2±22.8 51.9±32.8 0.001 0.001
HOMA-IR 4.15±3.87 5.60±5.79 12.60±8.14 0.001 0.001
QUICKI 0.33±0.04 0.32±0.04 0.28±0.02 0.001 0.001
Values are presented as mean±standard deviation.
BMI, body mass index; CPP, central precocious puberty; CA, chronological age; BA, bone age; SHBG, sex hormone binding globulin; LH, luteinizing 
hormone; E2, estradiol; FEI, free estradiol index; IGF-1, insulin-like growth factor-1; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment-insulin resistance; QUICKI, quantitative insulin 
sensitivity check index.   
*P-value was calculated by analysis of variance. †P for trend was calculated by trend test.
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of puberty include estrogen in food, cosmetics, and hair care 
products, endocrine disrupters in the environment, nutrition 
and obesity18­20). However, these factors remain controversial. 
For example, while there are several studies associating weight 
gain and obesity with earlier thelarche, there is not much 
support for the association between weight gain or obesity and 
earlier menarche10).
In our study, we analyzed the association between characteris­
tics of precocious puberty and insulin resistance. Baseline serum 
LH, E2, FEI, IGF­1, BA, insulin levels, and insulin resistance 
parameters were higher in the CPP group than in the control 
group. Although BMI SDS did not differ among the groups, 
insulin resistance parameters differed in the CPP and control 
groups. Because one of the roles of insulin is stimulating ovary 
and adrenal steroidogenesis, E2 and FEI levels might increase in 
girls with precocious puberty21). 
Another factor that modulates maturational timing is the 
GH/IGF­1 axis. The GH/IGF­1 axis is affected by glucose 
homeostasis22). Sørensen et al.23) showed that IGF­1 levels were 
significantly positively associated with insulin levels. While low 
IGF­1 serum concentrations are generally related to insulin 
resistance24), we found that insulin resistance and IGF­1 were 
significantly higher in the CPP group than in the control group. 
Due to limitation of the cross­sectional design of our study, a 
causal relationship between IGF­1 levels, insulin resistance, and 
pubertal timing could not be determined. However, we found a 
significant relationship between IGF­1 and insulin levels in girls 
with CPP.
In our study, girls with high BMI had increased BA, BA 
advancement, FEI, insulin levels, and HOMA­IR and lower 
SHBG and QUICKI than girls with low BMI. Because BA 
advancement and increased FEI are characteristic of sexual 
precocity, our data suggest that obesity is associated with sexual 
precocity. SHBG, a glycoprotein that binds sex hormones, also 
links obesity and precocious puberty25). Hyperinsulinemia 
from obesity­related insulin resistance can reduce hepatic 
SHBG production and increase sex steroid bioavailability26). 
In our study, insulin resistance was positively correlated with 
BA advancement and was negatively correlated with SHBG. 
We found that serum insulin levels were higher in girls with 
precocious puberty than in girls in the control group. High 
levels of insulin predict adverse cardiovascular risk factors 
Table 4. Multiple logistic regression results for change of bone age advancement associated with insulin resistance (n=330)
Model
HOMA-IR QUICKI x 100
β coefficient SE β OR (95% CI) P-value β coefficient SE β OR (95% CI) P-value
Unadjusted 0.177 0.083 1.19 (1.02–1.40) 0.033 -0.086 0.040 0.92 (0.85–0.99) 0.030
Model 1 0.174 0.081 1.19 (1.02–1.39) 0.031 -0.072 0.040 0.93 (0.86–1.01) 0.075
Model 2 0.183 0.086 1.20 (1.02–1.42) 0.033 -0.070 0.045 0.93 (0.85–1.02) 0.115
When insulin resistance increased, the odds for BA advancement increased. Model 1 is a multiple logistic regression adjusted for 
chronological age. Adjusted OR for chronological age and BMI represented in model 2. 
HOMA-IR, homeostasis model assessment-insulin resistance; QUICKI, quantitative insulin sensitivity check index; SE β, standard error of β 
coefficient; OR, odds ratio; CI, confidence interval; model 1, adjusted for chronological age (CA); model 2, adjusted for CA and body mass 
index (BMI).
Table 3. Pearson correlation for HOMA-IR and QUICKI in total girls (n = 330)
Variable
HOMA-IR QUICKI
Pearson correlation coefficient P-value Pearson correlation coefficient P-value
BA–CA 0.244 0.001 -0.235 0.001
Weight SDS 0.212 0.001 -0.195 0.001
Height SDS 0.394 0.001 -0.367 0.001
BMI SDS 0.398 0.001 -0.398 0.001
SHBG -0.215 0.001 0.254 0.001
LH 0.060 0.280 -0.111 0.044
FEI 0.109 0.048 -0.127 0.022
IGF-1 0.118 0.033 -0.174 0.002
AST -0.048 0.382 0.310 0.001
ALT 0.335 0.001 -0.085 0.121
Total cholesterol -0.114 0.039 0.027 0.630
Triglycerides 0.119 0.032 -0.170 0.102
LDL-cholesterol -0.165 0.003 0.116 0.035
Insulin resistance is positively correlated with BA advancement, BMI SDS, FEI, IGF-1, and triglycerides and was negatively correlated with 
SHBG.
HOMA-IR, homeostasis model assessment-insulin resistance; QUICKI, quantitative insulin sensitivity check index; BA, bone age; CA, 
chronological age; SDS, standard deviation scores; BMI, body mass index; SHBG, sex hormone binding globulin; LH, luteinizing hormone; 
FEI, free estradiol index; IGF-1, insulin-like growth factor-1; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDL, low-
density lipoprotein. 
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and metabolic syndrome. Insulin resistance in precocious 
puberty also might be associated with increased cardiovascular 
morbidity and mortality in adulthood8). Obviously, it is impor­
tant to prevent obesity and insulin resistance in children.
Obesity during childhood may lead to thelarche in girls10). It 
remains unclear whether early thelarche in overweight girls is 
related to central activation of the GnRH­gonadotropin axis27). 
Our findings show that girls with precocious puberty had high 
insulin resistance. Although we did not find a direct mechanism 
of GnRH­gonadotropin axis activation, the association between 
obesity and precocious puberty is important. 
One study suggested that obesity can lead to precocious 
puberty through leptin­induced pubertal development. Leptin 
serves as a signal to the hypothalamus regarding energy 
stores in adipose tissue and may directly stimulate GnRH and 
gonadotropin secretion28). Insulin and, paradoxically, obesity 
increase leptin levels29). Obesity­related insulin resistance with 
compensatory hyperinsulinemia increase serum leptin levels 
and may also play a role in early pubertal development. Further 
research is needed to identify the relationship between serum 
leptin levels and BA advancement.
BA studies can evaluate the rate of skeletal maturation, which 
can help diagnose conditions that delay or accelerate physical 
growth and development. Advanced BA is associated with 
earlier puberty30). We predicted the probability of precocious 
puberty through the quantification of insulin resistance and 
BA advancement. When insulin resistance increases, BA 
advancement occurs, which may results in precocious puberty. 
Our findings show that the risk of BA advancement increased 
119% when HOMA­IR increased by 1. Although there are 
multiple factors influencing precocious puberty, our results 
suggest that insulin resistance may be an important factor for 
CPP after adjusting for age and BMI. 
There was a limitation in our study to classify CPP and non­
CPP with peak LH. We defined CPP as peak LH≥5 IU/L and 
non­CPP as peak LH<5 IU/L. Accordingly, non­CPP group 
includes peripheral precocious puberty and slowly progressive 
CPP. In addition, the control group comprised girls who did 
not have secondary sexual character among the girls visited 
the hospital to check their puberty status. It is attributed to a 
hospital based observation study. 
In conclusion, our findings suggest that insulin resistance is 
elevated and associated with BA advancement in girls with CPP. 
Unlike other studies, our retrospective study included more 
than 100 patients with CPP from a single country. Longitudinal 
prospective studies that include more precise methods of 
evaluating body fat mass, such as triceps skin­fold thickness 
or waist circumference, are needed to determine the causality 
between obesity and precocious puberty.
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